Bazedoxifene-Conjugated Estrogens

• Menopausal Symptoms (Hot Flashes)
• Postmenopausal Osteoporosis Prevention
• Vasomotor Symptoms
• Bone Loss Prevention

Bazedoxifene/conjugated estrogens is a tissue selective estrogen complex (TSEC) combining a selective estrogen receptor modulator (SERM) with conjugated estrogens for the treatment of menopausal symptoms and prevention of osteoporosis. This combination provides estrogen benefits while mitigating endometrial stimulation risks.

Mechanism of Action

This combination product works through two complementary mechanisms. Conjugated estrogens bind to estrogen receptors (ER-alpha and ER-beta) and provide estrogenic effects on target tissues, relieving vasomotor symptoms (hot flashes) and preventing bone loss. Bazedoxifene is a SERM that acts as an estrogen agonist in some tissues (bone) and an antagonist in others (breast, uterus). By pairing these agents, the combination provides the benefits of estrogen therapy for menopausal symptoms and bone health while bazedoxifene antagonizes estrogen's proliferative effects on the endometrium, eliminating the need for concomitant progestin therapy.

Available Formulations

Bazedoxifene/conjugated estrogens is available as a fixed-dose oral tablet containing bazedoxifene 20 mg and conjugated estrogens 0.45 mg. The tablets should be taken once daily with or without food.

Medical Uses

This combination is FDA-approved for treatment of moderate to severe vasomotor symptoms (hot flashes, night sweats) associated with menopause and prevention of postmenopausal osteoporosis. It is intended for women with a uterus. Clinical trials demonstrated significant reductions in hot flash frequency and severity, as well as increases in bone mineral density at the spine and hip compared to placebo.

Dosing Guidelines

The recommended dose is one tablet (bazedoxifene 20 mg/conjugated estrogens 0.45 mg) taken orally once daily. The medication should be taken at approximately the same time each day. No dose adjustment is needed based on age. The medication has not been studied in patients with hepatic or severe renal impairment and should be used with caution in these populations. Treatment should use the lowest effective dose for the shortest duration consistent with treatment goals.

Important Safety Information

This product carries boxed warnings regarding endometrial cancer risk (when estrogen is used alone), cardiovascular disorders (increased risk of stroke and DVT), and probable dementia in women over 65. It is contraindicated in women with undiagnosed abnormal uterine bleeding, known or suspected estrogen-dependent neoplasia, active DVT/PE or history thereof, active arterial thromboembolic disease, known liver disease, and known protein C/S/antithrombin deficiency. Regular breast examinations and mammography are recommended.

Drug Interactions

CYP3A4 inducers (rifampin, phenobarbital, carbamazepine, St. John's Wort) may decrease conjugated estrogen and bazedoxifene levels. CYP3A4 inhibitors (ketoconazole, itraconazole) may increase levels. Concurrent use with other estrogens, progestins, or SERMs is not recommended. Thyroid hormone doses may need adjustment as estrogen increases thyroxine-binding globulin.

Special Populations

This medication is contraindicated during pregnancy and in women who may become pregnant. It should not be used during breastfeeding. The product is not indicated for use in pediatric patients. In elderly women (over 65 years), there may be increased risk of probable dementia. The medication has not been studied in patients with hepatic impairment; use is contraindicated in active liver disease. Caution is advised in severe renal impairment as the medication has not been adequately studied in this population.